WA-PATTERN-COMPUTER
21.6.2021 19:51:07 CEST | Business Wire | Press release
Pattern Computer,® Inc. (PCI) is excited to announce the discovery of new insights that can lead to significant reductions in the flights delays experienced across the United States.
According to the Federal Aviation Association (FAA)/Nextor, the estimated annual costs of delays, which includes direct costs to airlines and passengers, lost demand and indirect costs, in 2018 was $28 billion. Based on the Bureau of Transportation statistical data, 34% of all flights in 2018 experienced some type of departure delay and 18% of all flights experienced delays of 15 minutes or more, with an average delay of 66 minutes. The direct costs of those delays to airlines and passengers was $4.5 billion.
PCI’s team assembled a novel, integrated dataset which encompassed the FAA flight, aircraft and operational network data, and relevant US national weather data for the 7.2 million US commercial passenger flights in 2018.
Utilizing the Pattern Discovery Engine®, the PCI team was able to uncover a number of patterns underlying US commercial passenger flight delays. While many previous approaches focused on arrival delays, the PCI team chose to focus on flight departure delays as it more accurately reflects the operational efficiency of the individual airlines, as well as the airlines’ operational partnership with the FAA air traffic control facilities.
The most significant pattern, which was reflected as the top driver of delays in 11 of the 12 months, were flight departure delays due to weather factors along the route of travel, combined with the scheduled departure time (congestion). Together these two factors were the most consistent throughout the entirety of 2018. The flight leg for that day also played into this pattern in 10 of the 12 months as well – indicating that the cascading effect of flight delays continued to impact flights later in the day.
“When we used the Pattern Discovery Engine to understand the factors behind flight departure delays, we saw delays initiated by the FAA’s Traffic Management Initiatives due to en route weather as having created the most significant delays over the course of the year. The second most significant pattern was due to icing conditions at the departure airport, which also has cascading effects through the day for the impacted aircraft. A differentiating factor for Pattern Computer is that we do not see just one pattern; we see all the interrelated patterns in the dataset regarding a specific outcome in ranked order,” said Mark R. Anderson, CEO of Pattern Computer.
The newly discovered patterns indicate that most flight delays through the year were the results of significant weather events having regional limiting effects on the available flight routes. These large regional storms are typically predicted by the NOAA/FAA at least 48-72 hours in advance, airlines cancel flights ahead of the worst storms to avoid the high costs of long-delayed flights, including staffing costs, dissatisfied passengers, and crews cancelled due to duty-time expiration and required rest periods. While canceling flights is one option in reducing the costs of flight delays, the negative impact to customer satisfaction is high, and there is significant disruption to the airlines’ careful scheduling of crews, equipment and supporting staff. Too often the case is to carry on with the planned schedule and let the FAA determine how many planes are impacted as the weather event occurs. In many aspects, this is the same operating strategy as has been in effect for the past 4 decades.
“Due to the pandemic, the travel industry is facing a challenging period of uncertainty, but with that is the opportunity to improve operations, pricing, and offerings in a way that is future-ready. There is an opportunity to develop services tailored for the life styles, needs, and interests of business and leisure passengers alike. Post-pandemic, people are expecting a ‘new normal’ to emerge with many of the known patterns of life being different. Now is the time to introduce new capabilities, preparing for a post-pandemic swell in leisure travelers wishing to get out and travel,” said Bob Edwards, former CIO for United Airlines.
Without changes, the airlines will continue to bear substantial direct and indirect costs due to flight departure delays. But informed by these new Pattern discoveries, leading airlines could use technology, data and analytics combined with agility to create new solutions in the form of flexible scheduling, routing, pricing, and packaging to avoid these costs, which will only increase as the passenger loads begin to recover to their new normal, which may exceed the historical norms.
This work by Pattern Computer could allow informed, flexible scheduling. Dynamic load levels could be shifted and adjusted to the changing conditions, optimizing for costs, better utilizing available resources and resulting in more reliable schedules. Pattern is continually innovating and looking for ways to improve and optimize complex challenges in multiple industries, including the global airline industry, where new partnerships are now being sought.
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws, and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to air traffic operations, it is also making pattern discoveries for partners in several other sectors, including drug discovery and biomedical research, materials science, aerospace manufacturing, veterinary medicine, and finance.
For more information on Pattern Computer Inc., visit: www.patterncomputer.com
For more information about Mark Anderson, visit: www.patterncomputer.com/founders/
Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005713/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
